At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Targeting Anhedonia in Cocaine Use Disorder - Treatment Study
In Brief
A Phase 2 clinical trial evaluating d-amphetamine, Contingency management, and 1 other intervention for Cocaine-Related Disorders and Anhedonia. Completed, enrolled 57 participants across 1 site.
Detailed Summary
The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD). Specifically, this study will investigate how anhedonia affects outcomes in contingency management (CM) treatment for CUD and whether anhedonia mediates the effects of adjunctive treatment with a dopaminergic (DAergic) drug, d-amphetamine, on outcomes in CM for CUD, as well as investigate the contribution of anhedonia to overall CUD severity.
Study Details
Timeline
Interventions
Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
60 mg of riboflavin and cornstarch as needed.